Breaking News, Collaborations & Alliances

AbbVie, Teneobio Enter Drug Development Deal

Teneobio to receive $90 million upfront to develop a new treatment for multiple myeloma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie,  Teneobio, Inc. and its affiliate TeneoOne, Inc. have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.   TeneoOne will receive an upfront payment of $90 million and will continue developing TNB-383B through Phase 1. AbbVie will hold the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B.   B-cell maturation antigen (BCM...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters